Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring

Nardone OM1, Shivaji UN1, Ferruzza V1, Ghosh S1,2,3,4, Iacucci M1,2,3,4. Inflamm Bowel Dis. 2019 Oct 6. pii: izz226. doi: 10.1093/ibd/izz226. [Epub ahead of print]


Author information

Institute of Translational Medicine and Institute of Immunology and Immunotherapy, University of Birmingham, UK.

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.

NIHR Biomedical Research Centre, University of Birmingham and University Hospitals NHS Foundation Trust Birmingham, UK.

Department of Gastroenterology and Hepatology, University of Calgary, Alberta, Canada.


The traditional management of inflammatory bowel disease (IBD) based on symptom control is not considered valid anymore by most specialists in this field, and a new paradigm called "treat to target" has been introduced. This is based on the assessment of disease activity using objective measures. The identification of noninvasive biomarkers is crucial to diagnosis and monitor IBD because frequent endoscopic examinations are costly and uncomfortable for the patient. In this review, we focus on blood markers that may be able to assess mucosal healing (MH) in IBD and recent advances in this area. Introduction of commercial panel to predict MH opens the way for further developments so that colonoscopy or fecal markers may be avoided in some patients. This may also permit frequent monitoring for therapeutic response and achieve MH. It is a challenging area of research to identify a panel of biomarkers that may reflect inflammation and healing to serve as a surrogate of MH.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.